<strong>IMS</strong> COM PANY PRO FILES NOVARTIS Analyst Figures Financial analysts have provided the following forecasts for Novartis: COWEN & CO (January 2009) Key Figures for years ending December 31: Unit: $ mil lions, ex cept EPS in $ 2008 2009(E) 2010(E) 2011(E) 2012(E) Sales 41,459 43,110 49,775 54,245 58,590 EPS (continuing) 3.57 3.85 4.35 4.30 3.70 © 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 112
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS COWEN & CO (August 2008) Sales of Key Marketed Products for years ending December 31: Unit: $ mil lions 2007 2008(E) 2009(E) 2010(E) 2011(E) 2012(E) 2013(E) Diovan 5,012 5,985 6,405 6,400 4,650 3,200 1,500 Exforge 103 450 750 950 1,050 900 700 Lotrel 748 375 320 200 150 100 50 Lescol 665 640 550 450 300 200 100 Galvus 8 35 40 60 80 100 120 Total Cardiovascular 7,405 8,485 9,175 9,250 7,585 6,270 4,705 Glivec 3,050 3,820 4,305 4,550 4,750 4,950 5,100 Tasigna — 65 130 200 250 300 400 Zometa 1,297 1,370 1,385 1,200 1,000 900 750 Sandostatin 1,027 1,165 1,205 1,250 1,300 1,100 600 Femara 937 1,165 1,355 1,400 1,000 500 300 Exjade 357 515 625 675 725 775 825 Total Oncology 6,951 8,420 9,425 9,785 9,715 9,655 9,435 Trileptal 692 335 300 250 200 200 150 Exelon/Patch 632 790 885 950 975 900 800 Tegretol 413 485 495 505 515 525 535 Comtan Group 420 515 575 650 700 750 350 Ritalin Group 375 415 430 445 460 475 490 Total Neuroscience 3,345 3,345 3,530 3,670 3,835 4,010 3,660 Foradil 362 415 430 400 350 300 250 Xolair 140 190 200 225 250 275 300 TOBI (to be replaced by dry powder product in 2011) 273 295 310 180 — — — TMB 100 (2nd generation TOBI dry powder) — — — 150 345 360 370 Total Respiratory 959 1,090 1,190 1,305 1,470 1,935 2,395 Lucentis 397 975 1,220 1,350 1,400 1,450 1,500 Enablex 179 205 225 235 245 255 265 Zelnorm 88 15 20 10 10 10 10 Total Ophthalmics/GI/Urinary1,381 1,755 2,085 2,265 2,375 2,485 2,570 Voltaren 749 875 920 940 950 960 970 Aclasta 41 300 580 620 650 675 550 Prexige 91 45 40 40 40 40 40 Total Metabolic/Pain 1,574 1,745 2,060 2,160 2,245 2,325 2,130 Neoral/Sandimmun 944 1,030 1,005 985 955 925 900 Cubicin 14 20 40 50 75 100 125 Elidel 176 155 130 120 110 100 100 Total Immunology/ Infection 2,410 2,650 2,670 2,855 3,100 3,355 3,600 © 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 113